Efficacy and safety of low‐dose rifabutin‐based 7‐day triple therapy as a third‐ or later‐line Helicobacter pylori eradication regimen.

Autor: Inokuchi, Kazumi1 (AUTHOR), Mori, Hideki1,2 (AUTHOR), Matsuzaki, Juntaro1,3 (AUTHOR), Hirata, Kenro1 (AUTHOR), Harada, Yosuke1 (AUTHOR), Saito, Yoshimasa1,3,4 (AUTHOR), Suzuki, Hidekazu1,5 (AUTHOR), Kanai, Takanori1 (AUTHOR), Masaoka, Tatsuhiro1,6 (AUTHOR) masaoka@keio.jp
Zdroj: Helicobacter. Aug2022, Vol. 27 Issue 4, p1-10. 10p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje